Published in Front Immunol on October 24, 2016
Errors in data interpretation from genetic variation of human analytes. JCI Insight (2017) 0.75
Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science (2005) 6.48
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
Fcgamma receptors: old friends and new family members. Immunity (2006) 5.60
Significance of the positive crossmatch test in kidney transplantation. N Engl J Med (1969) 5.50
Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med (2016) 5.31
Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 5.31
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 4.84
Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2008) 4.10
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2011) 4.06
Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol (1983) 4.02
Chemotaxis of monocytes and neutrophils to platelet-derived growth factor. J Clin Invest (1982) 3.77
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity (1997) 3.22
Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol (2010) 2.66
Immunoglobulin G4: an odd antibody. Clin Exp Allergy (2009) 2.59
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant (2012) 2.46
Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J (1988) 2.40
IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol (1986) 2.36
Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant (2009) 2.27
Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood (2011) 2.15
Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J Immunol (2004) 2.04
C5a-induced expression of P-selectin in endothelial cells. J Clin Invest (1994) 1.93
Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant (2011) 1.91
Prominence of IgG4 in the IgG antibody response to human filariasis. J Immunol (1985) 1.91
Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant (2012) 1.90
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol (2013) 1.88
IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. J Immunol (2008) 1.68
NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant (2010) 1.62
Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol (2014) 1.60
The Synergistic Effect of Class II HLA Epitope-Mismatch and Nonadherence on Acute Rejection and Graft Survival. Am J Transplant (2015) 1.53
Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation (2001) 1.52
Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis. J Immunol (1993) 1.51
Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant (2015) 1.50
Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies. Transpl Int (2013) 1.50
C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation (2011) 1.43
De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. Transpl Int (2015) 1.43
Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol (2011) 1.40
Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant (2011) 1.40
Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A (2007) 1.39
Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation (2013) 1.33
Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol (2008) 1.33
Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes. J Exp Med (1996) 1.32
Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol (2007) 1.32
Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant (2010) 1.31
Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin Exp Immunol (2009) 1.31
HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol (2008) 1.31
Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection. J Immunol (2008) 1.28
Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation. Am J Transplant (2009) 1.27
Fc gamma receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Dis (1994) 1.25
C4d fixing, luminex binding antibodies - a new tool for prediction of graft failure after heart transplantation. Am J Transplant (2007) 1.24
Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant (2010) 1.23
De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant (2011) 1.22
The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant (2011) 1.20
Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am J Transplant (2014) 1.19
Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients. Hum Immunol (2000) 1.18
Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant (2012) 1.18
In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ Res (2008) 1.17
Preferential priming of alloreactive T cells with indirect reactivity. Am J Transplant (2009) 1.15
Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation (2010) 1.15
Non-complement- and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am J Transplant (2004) 1.14
Membrane attack complex contributes to destruction of vascular integrity in acute lung allograft rejection. J Immunol (2002) 1.13
Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant (2012) 1.13
Variable domain-identical antibodies exhibit IgG subclass-related differences in affinity and kinetic constants as determined by surface plasmon resonance. Mol Immunol (1994) 1.13
Antibodies of different human IgG subclasses show distinct patterns of affinity maturation after immunization with keyhole limpet haemocyanin. Immunology (1990) 1.12
IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest (2013) 1.12
Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun (2011) 1.11
The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation (2013) 1.11
Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol (1998) 1.10
Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl (2012) 1.10
Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent manner. J Immunol (2002) 1.07
IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. J Am Soc Nephrol (2015) 1.07
HLA class I molecules partner with integrin β4 to stimulate endothelial cell proliferation and migration. Sci Signal (2010) 1.06
Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation (2002) 1.06
Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am J Transplant (2012) 1.06
Cross-linking of MHC class II molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T cell activation. J Immunol (1996) 1.05
Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant (2005) 1.05
Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses. Immunology (1996) 1.05
Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation (2009) 1.05
NK cell patrolling and elimination of donor-derived dendritic cells favor indirect alloreactivity. J Immunol (2010) 1.04
Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol (2009) 1.04
Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation (2011) 1.03
Pathways of major histocompatibility complex allorecognition. Curr Opin Organ Transplant (2008) 1.02
HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcγRs. J Immunol (2013) 1.02
Antibodies to purified bee venom proteins and peptides. II. A detailed study of changes in IgE and IgG antibodies to individual bee venom antigens. J Allergy Clin Immunol (1983) 1.02
Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells. Circulation (2013) 1.00
Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J Immunol (2001) 1.00
HLA and MICA: targets of antibody-mediated rejection in heart transplantation. Transplantation (2011) 0.99
mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci U S A (2014) 0.98
Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant (2012) 0.98
Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver. Am J Transplant (2012) 0.97
Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation (2006) 0.96
Pathways of helper CD4 T cell allorecognition in generating alloantibody and CD8 T cell alloimmunity. Transplantation (2007) 0.95
Complement regulation of T cell immunity. Immunol Res (2012) 0.95
Fc gamma RIIa polymorphism: a susceptibility factor for immune complex-mediated lupus nephritis in Brazilian patients. Nephrol Dial Transplant (2004) 0.95
B-lymphocytes support and regulate indirect T-cell alloreactivity in individual patients with chronic antibody-mediated rejection. Kidney Int (2015) 0.94
Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther (2014) 0.94
Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? Transpl Immunol (2013) 0.92
Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss. Hum Immunol (2007) 0.92
Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant (2011) 0.91